Gruenenthal Gmbh

Grunenthal Gmbh

Amgen Inc.

Otto Ficker Ag

Alantos Pharmaceuticals Holding, Inc.

Atlantos Pharmaceuticals Holding, Inc.

Peter Greven Physioderm Gmbh

Bert Nolte

Klaus Linz

Werner Guenter Englberger

Hans Schick

Wolfgang Schröder

Helmut Sonnenschein

Arthur G Taveras

Christoph Steeneck

József Bálint

Matthias Schneider

Birgit Braun

Hongbo Deng

Christian Gege

Xinyuan Edward Wu

Saskia Zemolka

Irving Sucholeiki

Matthias Hochgürtel

Frank Richter

Sigrid Ozegowski

Babette-Yvonne Koegel

Paul Ratcliffe

Olga Groeger

Stefan Schunk

Fritz-Frieder Frickel

Michael Essers

Derek John Saunders

Sven Kühnert

Heinz Graubaum

Fritz Theil

Brian M Gallagher, Jr

Heiko Kroth

Tim Feuerstein

Anita Wegert

Torsten Arndt

Harald Bluhm

Ralf Biesinger

Stephanie Harlfinger

Claudia Hinze

Sven Kuehnert

Birgitta Henkel

Sven Frormann

Rene Michael Koenigs

Babette-Yvonne Kögel

Hermann Josef Stolz

René Michael Koenigs

Birgit Roloff

Jens Kaufmann

Carine Chevrier

Michael Bosies

Joshua Van Veldhuizen

Siegfried Leonhardt

Michael Essors

Jürgen Boer

Julian Gebauer

Matthias Hochguertel

Robert Börnicke

Olga GRÖGER

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the &#x3bc; opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

Substituted azaspiro(4.5)decane derivatives

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the &#x3bc; opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

The invention relates to compounds that have an affinity to the &#x3bc;-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Substituted 4-aminocyclohexane derivatives

The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R, R, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

Heterobicyclic metalloprotease inhibitors

The invention relates to compounds that have an affinity to the &#x3bc;-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain or other conditions.

Substituted cyclohexyldiamines

Substituted spirocyclic cyclohexane derivatives

The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.

Dipeptidyl peptidase-IV inhibitors

(Hetero)aryl cyclohexane derivatives

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R, R, R, and Rare as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

An envelope consisting of a front side and a rear side which are interconnected by side flaps, has a fold-back flap to which a layer of contact adhesive is applied. The adhesive used is a strong contact adhesive which is effective without moistening or activation by any other means. The fold-back flap is laid against the rear side of the envelope for the purposes of transport and storage, an area coated with a parting agent being provided so that the adhesive can be detached before use. The envelope is closed by pressing the otherwise uncoated closing flap onto the adhesive-coated fold-back flap. The adhesive is applied to the fold-back flap by transfer, i.e. the adhesive is applied to the parting agent layer during production and then transferred to the fold-back flap when the latter is redressed.

Envelope with an adhesive closure and method and device for producing the same

In the process of packaging letter envelopes and mailing wallets, the packaging batch is counted in the end region of the production machine, and the individual article of the packaging batch corresponding to the specific batch size is at least identified or optionally pushed a certain distance sideways out of the path of movement of the packaging batch in one direction or the other as a counting article. The packaging batch is deposited on a conveyor belt and conveyed away. A stack support keeps the stack approximately vertical on its end face. The stack support is advanced in front of the stack at the conveying speed of the conveyor belt. As soon as the counting article at the end of a stack has arrived at a transfer point which is at a relatively long distance from the production machine, a separating device is introduced into the stack, with the result that the following portion of the packaging batch is temporarily halted. During this time, the separated stack is pushed, at the same height, into an open container via a slide track. Subsequently, the stack support is guided back to the separation point, and the separating device is retracted from the end face of the following packaging batch, after which the stack support once again takes over the vertical guidance of the packaging batch, until the next counting article has arrived at the separation point. The automatic packaging machine for letter envelopes and mailing wallets has several devices, by means of which the individual steps of the process are executed partly alone and partly in combination with one another.

Process for automatically packaging letter envelopes and mailing wallets

Growing community of inventors

Aachen, Germany

Bert Nolte